Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

XREF LIMITED Share Issue/Capital Change 2018

Dec 4, 2018

66097_rns_2018-12-04_fa0f77c4-053a-4313-a5d8-19959ee99359.pdf

Share Issue/Capital Change

Open in viewer

Opens in your device viewer

==> picture [132 x 56] intentionally omitted <==

5 December 2018

Company Announcements Office Australian Securities Exchange

Issue of Options

Xref Limited (ASX:XF1) (Xref or the Company) advises that a total of 3,715,664 options have been issued under the terms of the Employee Option Plan (EOP) to 31 of the Company’s employees, two of its contractors and to Xref’s Chief Operating Officer (COO).

The 315,664 options issued to the employees and contractors have an exercise price of $0.66, vest on 1 August 2019 and will expire if not exercised by 1 August 2022.

The 2,500,000 options issued to five senior staff members have an exercise price of $0.70 and expire if not exercised by 29 November 2022. The first tranche of 1,250,000 options vested on the date of issue and the second tranche of 1,250,000 options vest on the fiveyear anniversaries of the five employees’ joining dates (i.e. vest between November 2018 and March 2020).

The 900,000 options issued to Xref’s COO have an exercise price of $0.70, vest in three tranches (with the first tranche of 300,000 options that were vested on the date of issue and expire if not exercised by 3 September 2021, the second tranche of 300,000 options vesting on 3 September 2019 and expire if not exercised by 3 September 2022, and the third tranche of 300,000 options vesting on 3 September 2020 and expire if not exercised by 3 September 2023).

The Company also advises that 15,909 options at an exercise price of $0.66 per option and have expired. The options were held under Xref’s EOP and expired when the two relevant staff members left the Company.

An Appendix 3B for the issue of these options is attached.

Xref Limited

Robert J Waring

Company Secretary

Cleansing Statement – Notice under Section 708A(5)(e)

As at 5 December 2018, Xref Limited gives notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) (Corporations Act) that:

  1. the Company issued the abovementioned securities without disclosure to investors under Part 6D.2 of the Corporations Act.

  2. the Company has complied with the provisions, as they apply to the Company, of Chapter 2M of the Corporations Act and with Section 674 of the Corporations Act; and

  3. there is no information:

  4. a. that has been excluded from a continuous disclosure notice in accordance with the ASX Listing Rules; or

  5. b. that investors and their professional advisors would reasonably require for the purpose of making an informed assessment of the assets and liabilities, financial performance, profits and losses and prospects of Xref Limited, or the rights and liabilities attaching to Xref Limited ordinary shares.

==> picture [84 x 18] intentionally omitted <==

Xref Limited (ASX:XF1) ACN 122 404 666 Suite 17, Level 3, 13 Hickson Road, Dawes Point, Sydney NSW 2000 Australia, Website: xref.com

Appendix 3B New issue announcement

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

Xref Limited (ASX:XF1)

ABN

34 122 404 666

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1
+Class of+securities issued or to
be issued
2
Number of+securities issued or to
be issued (if known) or maximum
number which may be issued
3
Principal terms of the+securities
(e.g. if options, exercise price and
expiry
date;
if
partly
paid
+securities,
the
amount
outstanding and due dates for
payment;
if
+convertible
securities, the conversion price
and dates for conversion)
Options
A total of 3,715,664 options
All 3,715,664 options were issued under the
terms of the Xref Employee Option Plan (EOP).
There were 315,664 options issued to employees
and contractors with an exercise price of $0.66,
which vest on 1 August 2019 and will expire if not
exercised by 1 August 2022.
There were 2,500,000 options issued to five senior
staff members, which have an exercise price of $0.70
and expire if not exercised by 29 November 2022.
The first tranche of 1,250,000 options vested on the
date of issue and the second tranche of 1,250,000
options vest on the five-year anniversaries of the
five employees’ joining dates (i.e. vest between
November 2018 and March 2020).
There were 900,000 options issued to Xref’s Chief
Operating Officer (COO) with an exercise price of
$0.70, which vest in three tranches (with the first
tranche of 300,000 options that were vested on the
date of issue and expire if not exercised by
3 September 2021, the second tranche of 300,000
options vesting on 3 September 2019 and expire
if not exercised by 3 September 2022, and the
third tranche of 300,000 options vesting on
3 September 2020 and expire if not exercised by
3September 2023).
  • See chapter 19 for defined terms.

Appendix 3B Page 1

04/03/2013

Appendix 3B New issue announcement

4 Do the[+] securities rank equally Any fully paid ordinary shares issued, if and in all respects from the[+] issue when the options are exercised, will rank date with an existing[+] class of equally with the Company’s existing fully quoted[+] securities? paid ordinary shares. If the additional[+] securities do not rank equally, please state:  the date from which they do  the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

5 Issue price or consideration All options were issued for no consideration under the terms of the EOP. The 315,664 options issued to the employees have an exercise price of $0.66. The 2,500,000 options issued to senior staff members have an exercise price of $0.70. The 900,000 options issued to the COO have an exercise price of $0.70. 6 Purpose of the issue The total of 3,715,664 options was issued (If issued as consideration for under the terms of the EOP to 31 of Xref’s the acquisition of assets, clearly employees, two of its contractors and the identify those assets) Company’s COO. 6a Is the entity an[+] eligible entity Yes that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b – 6h in relation to the[+] securities the subject of this Appendix 3B , and comply with section 6i 6b The date the security holder The Company received shareholder resolution under rule 7.1A was passed approval at its Annual General Meeting held on 28 November 2018 under ASX Listing Rule 7.1A. 6c Number of[+] securities issued without security holder approval Not applicable under rule 7.1

  • See chapter 19 for defined terms.

Appendix 3B Page 2

04/03/2013

Appendix 3B New issue announcement

6d Number of[+] securities issued with security holder approval Not applicable under rule 7.1A 6e Number of[+] securities issued with security holder approval under rule 7.3, or another Not applicable specific security holder approval (specify date of meeting) 6f Number of[+] securities issued 3,715,664 options under an exception in rule 7.2 6g If[+] securities issued under rule 7.1A, was the issue price at least 75% of 15 day VWAP as calculated under Not applicable rule 7.1A.3? Include the[+] issue date and both values. Include the source of the VWAP calculation. 6h If[+] securities were issued under rule 7.1A for non-cash consideration, state date on Not applicable which valuation of consideration was released to ASX Market Announcements 6i Calculate the entity’s remaining issue capacity under rule 7.1 and rule 7.1A – 40,896,425 complete Annexure 1 and release to ASX Market Announcements 7 +Issue dates Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a 4 December 2018 pro rata entitlement issue must comply with the applicable timetable in Appendix 7A. Cross reference: item 33 of Appendix 3B. 8 Number and +class of all Number +Class +securities quoted on ASX ( including the +securities in 163,585,697 Fully paid ordinary shares section 2 if applicable) Number +Class 9 Number and +class of all 16,666,666 C Class Performance Rights – +securities not quoted on ASX The conversion ratio of the ( including the +securities in Performance Rights into ordinary section 2 if applicable) shares upon achievement of the relevant Performance Milestone is one ordinary share for each Performance Right.

  • See chapter 19 for defined terms.

Appendix 3B Page 3

04/03/2013

Appendix 3B New issue announcement

*220,070 options less 15,909 options
equal 204,161 options, relating to two
staff members who left the Company
and therefore their options have expired.
Number +Class
1,992,673
7,000,000
900,000
906,870
*204,161
2,500,000
315,664
2,500,000
900,000
Options – will expire, if not exercised, by
1 February 2019 – exercise price $0.23
(all of which have vested).
Options – 4,500,000 of the Options will expire,
if not exercised, by 25 November 2021 and
2,500,000 of the Options will expire, if not
exercised, by 25 November 2022. All have an
exercise price of $0.70 (4,500,000 of which
have vested and 2,500,000 will vest on
25 November 2019).
Options – will expire, if not exercised, by
25 November 2021. All have an exercise
price of $0.70 (all of which have vested).
Options – issued under the EOP, with an
exercise price of $0.585 (all of which have
vested) and will expire if not exercised by
3 July 2021.
Options – issued under the EOP, with
an exercise price of $0.66 (which vest
on 5 February 2019) and will expire if
not exercised by 5 February 2022.
Options – issued under the EOP, with an
exercise price of $0.70 (with 1,000,000 options
of which have vested and expiring if not
exercised by 12 February 2021, with 750,000
options vesting on 12 February 2019 and will
expire if not exercised by 12 February 2022, and
with 750,000 options vesting on the later of
12 February 2020 or when the Company
achieves cash flow breakeven and expiring if
not exercised by 12 February 2023).
Options – issued under the EOP, with
an exercise price of $0.66, which vest
on 1 August 2019 and will expire if not
exercised by 1 August 2022.
Options – issued under the EOP, with an
exercise price of $0.70 and will expire if not
exercised by 29 November 2022 (1,250,000
of which have vested and 1,250,000 options
vest on dates until March 2020).
Options – issued under the EOP, with an
exercise price of $0.70 (300,000 options of
which have vested and expire if not exercised
by 3 September 2021, with 300,000 options
vesting on 3 September 2019 and expiring if
not exercised by 3 September 2022, and with
300,000 options vesting on 3 September 2020
and expiringif not exercised by3 September 2023).
  • See chapter 19 for defined terms.

Appendix 3B Page 4

04/03/2013

Appendix 3B New issue announcement

  • 10 Dividend policy (in the case of a Any fully paid ordinary shares issued on the trust, distribution policy) on the exercise of options will have full increased capital (interests) participation in any future dividends.

Part 2 - Pro rata issue

Questions 11 to 33 are not applicable

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

  • 34 Type of[+] securities

  • ( tick one )

  • (a) +Securities described in Part 1

  • (b)[All other ][+][securities ]

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

  • 35 If the[+] securities are[+] equity securities, the names of the 20 largest holders of the additional[+] securities, and the number and percentage of additional[+] securities held by those holders

  • 36 If the[+] securities are[+] equity securities, a distribution schedule of the additional +securities setting out the number of holders in the categories

  • 1 - 1,000

  • 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over

  • 37 A copy of any trust deed for the additional[+] securities

Entities that have ticked box 34(b)

Questions 38 to 42 are not applicable

  • See chapter 19 for defined terms.

Appendix 3B Page 5

04/03/2013

Appendix 3B New issue announcement

Quotation agreement

1 +Quotation of our additional +securities is in ASX’s absolute discretion. ASX may quote the[+] securities on any conditions it decides.

  • 2 We warrant the following to ASX.

  • The issue of the[+] securities to be quoted complies with the law and is not for an illegal purpose.

  • There is no reason why those[+] securities should not be granted[+] quotation.

  • An offer of the[+] securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

    • Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty
  • Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any[+] securities to be quoted and that no-one has any right to return any[+] securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the[+] securities be quoted.

  • If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the[+] securities be quoted.

  • 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

  • 4 We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Date: 5 December 2018 ( ~~Director/~~ Company Secretary) Print name: Robert J Waring

== == == == ==

  • See chapter 19 for defined terms.

Appendix 3B Page 6

04/03/2013

Appendix 3B New issue announcement

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital

Step 1: Calculate “A”, the base figure from which the placement capacity is calculated

Part 1 Part 1
Rule 7.1 – Issues exceeding 15% of capital
Step 1: Calculate “A”, the base figure from which the placement
capacity is calculated
Insertnumber of fully paid+ordinary
securities on issue 12 months before the
+issue date or date of agreement to issue
147,736,127
Addthe following:
• Number of fully paid+ordinary securities
issued in that 12-month period under an
exception in rule 7.2
• Number of fully paid+ordinary securities
issued in that 12-month period with
shareholder approval
• Number of partly paid+ordinary
securities that became fully paid in that
12-month period
Note:
• Include only ordinary securities here –
other classes of equity securities cannot
be added
• Include here (if applicable) the securities
the subject of the Appendix 3B to which
this form is annexed
• It may be useful to set out issues of
securities on different dates as separate
line items
Date
Number
26 Sep 2018
550,000
28 Sep 2018
13,333,334
5 Oct 2018
1,966,236
Total
15,849,570
Subtractthe number of fully paid
+ordinary securities cancelled during that
12-month period
Nil
“A” 163,585,697
  • See chapter 19 for defined terms.

Appendix 3B Page 7

04/03/2013

Appendix 3B New issue announcement

Step 2: Calculate 15% of “A”

“B” 0.15 [Note: this value cannot be changed] Multiply “A” by 0.15 24,537,855

Step 3: Calculate “C”, the amount of placement capacity under rule 7.1 that has already been used

Insert number of[+] equity securities issued or agreed to be issued in that 12-month period not counting those issued:

  • Under an exception in rule 7.2

  • Under rule 7.1A

  • With security holder approval under rule 7.1 or rule 7.4

Note:

  • This applies to equity securities, unless specifically excluded – not just ordinary securities

  • Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed

  • It may be useful to set out issues of securities on different dates as separate line items

“C” Nil

Step 4: Subtract “C” from [“A” x “B”] to calculate remaining placement capacity under rule 7.1

“A” x 0.15

24,537,855

Note: number must be same as shown in Step 2

Subtract “C”

Note: number must be same as shown in Step 3

Total [“A” x 0.15] – “C”

Nil 24,537,855 [Note: this is the remaining placement capacity under rule 7.1]

  • See chapter 19 for defined terms.

Appendix 3B Page 8

04/03/2013

Appendix 3B New issue announcement

Part 2

Rule 7.1A – Additional placement capacity for eligible entities

Step 1: Calculate “A”, the base figure from which the placement capacity is calculated

“A” 163,585,697 Note: number must be same as shown in Step 1 of Part 1

Step 2: Calculate 10% of “A”

“D” 0.10 Note: this value cannot be changed Multiply “A” by 0.10 16,358,570

Step 3: Calculate “E”, the amount of placement capacity under rule 7.1A that has already been used

Insert number of[+] equity securities issued or agreed to be issued in that 12-month period under rule 7.1A Nil

Notes:

  • This applies to equity securities – not just ordinary securities

  • Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed

  • Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained

  • It may be useful to set out issues of securities on different dates as separate line items

“E” Nil

Step 4: Subtract “E” from [“A” x “D”] to calculate remaining placement capacity under rule 7.1A

Step 4: Subtract “E” from [“A” x “D”] to calculate remaining
placement capacity under rule 7.1A
Step 4: Subtract “E” from [“A” x “D”] to calculate remaining
placement capacity under rule 7.1A
“A” x 0.10
Note: number must be same as shown in Step 2

16,358,570
Subtract“E”
Note: number must be same as shown in Step 3

Nil
Total[“A” x 0.10] – “E” 16,358,570
Note: this is the remaining placement
capacity under rule 7.1A
  • See chapter 19 for defined terms.

Appendix 3B Page 9

04/03/2013